Lisdexamfetamine Dimesylate

Drug Usage Statistics, United States, 2004 - 2014

Number of Prescriptions Over Time (2004 - 2014)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2007 563 -
2008 183  380
2009 145  38
2010 147  2
Year Rank Change
2011 94  53
2012 87  7
2013 101  14
2014 91  10

Patient Out-Of-Pocket Cost Over Time (2004 - 2014)

"Out-of-pocket" cost refers to the payment made by the patient (either cash price or the copay amount). This value does not include reimbursement from a third party payer (eg, Medicare or private insurance) and does not represent the total drug cost.

Usage Statistics of Related Drugs

Drug Name Total Prescriptions (2014)
Amphetamine 15,905,052
Methylphenidate 15,505,256
Lisdexamfetamine Dimesylate (this drug) 8,394,655
Dexmethylphenidate Hydrochloride 3,194,850

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Vyvanse
Generic Drug Synonyms and Salts
  • Lisdexamfetamine Dimesylate

FDA Approval Information

Established Pharmacologic Class (EPC): Central Nervous System Stimulant
Initial FDA approval date: 2/23/2007
First FDA applicant: Shire Development Inc
First dosage form: Capsule (oral)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2004-2014. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 17.0. Read more about the ClinCalc DrugStats database.

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

Which of these drugs causes acute kidney injury? The Top 250 Drugs by ClinCalc Academy
©2017 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Mar 4, 2017
Back to Top
Top